featured
Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide in Patients With Advanced Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the National Cancer Institute
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer
J. Natl. Cancer Inst 2022 Apr 13;[EPub Ahead of Print], LY Lai, MK Oerline, MEV Caram, PA Tsao, SR Kaufman, BK Hollenbeck, VB ShahinianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.